For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.

Researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key switch that has the potential to eliminate dormant HIV reservoirs.

Trucode Gene Repair Inc. emerged from stealth mode with $34 million in financing to bolster the biotech startup’s triplex gene-editing technology.

Researchers with the Salk Institute developed a new type of gene editing called SATI that may provide the option of editing numerous gene mutation diseases such as Huntington’s disease and the rare premature aging syndrome, progeria.

Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.

GlaxoSmithKline struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California.

Vertex Pharmaceuticals will acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.

Alphabet’s venture capital arm GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.

Durham, N.C.-based Precision BioSciences set the company’s initial public offering price at $16 per share, raising $126.4 million.